• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

G12V突变是中国胃癌患者的不良预后因素。

G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients.

作者信息

Fu Xin-Hui, Chen Zhi-Ting, Wang Wen-Hui, Fan Xin-Juan, Huang Yan, Wu Xiao-Bin, Huang Jing-Lin, Wang Jing-Xuan, Lin Han-Jie, Tan Xiao-Li, Wang Lei, Wang Jian-Ping

机构信息

Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China.

Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China.

出版信息

J Cancer. 2019 Jan 29;10(4):821-828. doi: 10.7150/jca.27899. eCollection 2019.

DOI:10.7150/jca.27899
PMID:30854087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6400811/
Abstract

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the , , and mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of , and mutations were 4.1%, 1.2% and 3.5%, respectively. mutations were significantly concentrated in stage III and IV gastric cancer (=0.009). G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (=0.013). In conclusion, only the G12V mutation has an adverse effect on patient survival.

摘要

本研究旨在调查中国胃癌患者的分子特征。在我们的研究中,通过桑格测序分析了485例胃癌患者的 、 和 突变状态。采用Kaplan-Meier分析根据不同基因型绘制生存曲线。结果显示, 、 和 突变的频率分别为4.1%、1.2%和3.5%。 突变显著集中在III期和IV期胃癌(=0.009)。G12V突变携带者的总生存期比其他突变携带者和野生型组患者短得多(=0.013)。总之,只有 G12V突变对患者生存有不利影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/67f843eab23f/jcav10p0821g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/fde9225ee3a5/jcav10p0821g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/67caf2fd9a60/jcav10p0821g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/67f843eab23f/jcav10p0821g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/fde9225ee3a5/jcav10p0821g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/67caf2fd9a60/jcav10p0821g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa52/6400811/67f843eab23f/jcav10p0821g003.jpg

相似文献

1
G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients.G12V突变是中国胃癌患者的不良预后因素。
J Cancer. 2019 Jan 29;10(4):821-828. doi: 10.7150/jca.27899. eCollection 2019.
2
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.BRAF、PIK3CA和HER2致癌性改变与晚期结直肠癌远处转移的KRAS突变状态的关系
PLoS One. 2016 Mar 18;11(3):e0151865. doi: 10.1371/journal.pone.0151865. eCollection 2016.
3
KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.126例胰腺癌中的KRAS、BRAF和PIK3CA突变与患者预后:焦磷酸测序技术及文献综述
Med Oncol. 2016 Apr;33(4):32. doi: 10.1007/s12032-016-0745-9. Epub 2016 Feb 29.
4
Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.KRAS、NRAS、BRAF和PIK3CA突变在接受贝伐单抗治疗的转移性结直肠癌患者中的意义:单机构经验
Acta Med Litu. 2016;23(1):24-34. doi: 10.6001/actamedica.v23i1.3267.
5
Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.壶腹腺癌中KRAS、BRAF和PIK3CA突变的低发生率及其预后价值。
Hum Pathol. 2016 Apr;50:90-100. doi: 10.1016/j.humpath.2015.11.009. Epub 2015 Nov 30.
6
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.G12V和G12A KRAS突变与接受贝伐单抗治疗的转移性结直肠癌患者的不良预后相关。
Tumour Biol. 2016 May;37(5):6823-30. doi: 10.1007/s13277-015-4523-7. Epub 2015 Dec 10.
7
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.BRAF和KRAS突变状态在II期和III期微卫星不稳定结肠癌中的预后价值
Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23.
8
[Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].实时定量PCR-桑格测序法与TaqMan探针法检测结直肠癌KRAS/BRAF突变的比较分析
Zhonghua Bing Li Xue Za Zhi. 2014 Feb;43(2):77-82.
9
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.根据KRAS、NRAS和BRAF突变以及KRAS突变变体的结果:AIO结直肠癌研究组对五项转移性结直肠癌随机试验的汇总分析。
Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.
10
The Prognostic Value of Microsatellite Instability, and Mutations in Stage II Colon Cancer Patients.微卫星不稳定性及II期结肠癌患者基因突变的预后价值
Mol Med. 2016 May;21(1):1038-1046. doi: 10.2119/molmed.2015.00220. Epub 2016 May 9.

引用本文的文献

1
Precancerous pathways to gastric cancer: a review of experimental animal models recapitulating the correa cascade.胃癌的癌前病变途径:对重现科雷亚级联反应的实验动物模型的综述
Front Cell Dev Biol. 2025 Jul 2;13:1620756. doi: 10.3389/fcell.2025.1620756. eCollection 2025.
2
Synergistic induction of autophagy in gastric cancer by targeting CDK4/6 and MEK through AMPK/mTOR pathway.通过AMPK/mTOR途径靶向CDK4/6和MEK对胃癌自噬的协同诱导作用。
Heliyon. 2024 Apr 29;10(9):e30475. doi: 10.1016/j.heliyon.2024.e30475. eCollection 2024 May 15.
3
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

本文引用的文献

1
LinkedOmics: analyzing multi-omics data within and across 32 cancer types.LinkedOmics:在 32 种癌症类型内和类型间分析多组学数据。
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963. doi: 10.1093/nar/gkx1090.
2
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.PIK3CA突变在胃癌中的预后及临床影响:焦磷酸测序技术与文献综述
BMC Cancer. 2016 Jul 7;16:400. doi: 10.1186/s12885-016-2422-y.
3
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
肺癌中通过遗传/非遗传机制获得对 KRAS G12C 小分子抑制剂的耐药性。
Sci Adv. 2023 Oct 13;9(41):eade3816. doi: 10.1126/sciadv.ade3816.
4
Development of alternative herbals remedy for gastric cancer based on transcriptomic analysis of immune infiltration and ferroptosis.基于免疫浸润和铁死亡转录组分析开发胃癌替代草药疗法
Front Genet. 2023 Mar 3;14:1086368. doi: 10.3389/fgene.2023.1086368. eCollection 2023.
5
In Silico Strategies for Designing of Peptide Inhibitors of Oncogenic K-Ras G12V Mutant: Inhibiting Cancer Growth and Proliferation.用于设计致癌性K-Ras G12V突变体肽抑制剂的计算机模拟策略:抑制癌症生长和增殖
Cancers (Basel). 2022 Oct 6;14(19):4884. doi: 10.3390/cancers14194884.
6
Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing.基于下一代测序技术检测一组在胃癌中具有高突变频率的24个新基因。
World J Clin Cases. 2022 May 26;10(15):4761-4775. doi: 10.12998/wjcc.v10.i15.4761.
7
MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.MEK 抑制可抑制 KRAS 突变型胃癌的转移进展。
Cancer Sci. 2022 Mar;113(3):916-925. doi: 10.1111/cas.15244. Epub 2022 Jan 7.
8
BRAF Mutation Is Associated with Hyperplastic Polyp-Associated Gastric Cancer.BRAF 突变与增生性息肉相关的胃癌相关。
Int J Mol Sci. 2021 Nov 25;22(23):12724. doi: 10.3390/ijms222312724.
9
gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor.胃印戒细胞癌患者的基因状态,并作为MEK抑制剂的生物标志物。
J Gastrointest Oncol. 2021 Jun;12(3):1020-1030. doi: 10.21037/jgo-20-617.
10
Identification of a novel heterozygous germline RAD52 missense mutation in a patient with gallbladder carcinoma: A case report.鉴定一名胆囊癌患者中新型 RAD52 错义突变的杂合胚系突变:病例报告。
Medicine (Baltimore). 2021 May 14;100(19):e25957. doi: 10.1097/MD.0000000000025957.
阿司匹林用于心血管疾病和结直肠癌的一级预防:美国预防服务工作组推荐声明。
Ann Intern Med. 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577. Epub 2016 Apr 12.
4
KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients.通过液滴数字PCR检测结直肠癌患者循环游离DNA中的KRAS G12V突变
Int J Mol Sci. 2016 Apr 1;17(4):484. doi: 10.3390/ijms17040484.
5
HistoMosaic Detecting KRAS G12V Mutation Across Colorectal Cancer Tissue Slices through in Situ PCR.组织镶嵌技术通过原位PCR检测结直肠癌组织切片中的KRAS G12V突变
Anal Chem. 2016 Mar 1;88(5):2792-8. doi: 10.1021/acs.analchem.5b04460. Epub 2016 Feb 12.
6
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.G12V和G12A KRAS突变与接受贝伐单抗治疗的转移性结直肠癌患者的不良预后相关。
Tumour Biol. 2016 May;37(5):6823-30. doi: 10.1007/s13277-015-4523-7. Epub 2015 Dec 10.
7
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.KRAS G12V突变在841例接受手术切除的白种人肺腺癌病例中的预后价值。
Br J Cancer. 2015 Oct 20;113(8):1206-15. doi: 10.1038/bjc.2015.327. Epub 2015 Sep 15.
8
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.KRAS作为II期和III期结直肠癌患者预后不良及术后FOLFOX化疗获益的预测指标。
Mol Oncol. 2015 Aug;9(7):1341-7. doi: 10.1016/j.molonc.2015.03.006. Epub 2015 Mar 27.
9
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.胃癌患者中KRAS和PIK3CA而非BRAF突变的鉴定。
Mol Med Rep. 2015 Jul;12(1):1219-24. doi: 10.3892/mmr.2015.3530. Epub 2015 Mar 23.
10
Annual report on status of cancer in China, 2011.《2011年中国癌症现状年度报告》
Chin J Cancer Res. 2015 Feb;27(1):2-12. doi: 10.3978/j.issn.1000-9604.2015.01.06.